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Abstract
Background: Interleukin-8 (IL-8) is a cytokine that plays an important role in tumor progression
in a variety of cancer types; however, its regulation is not well understood in oral cancer cells. In
the present study, we examined the expression and mechanism of IL-8 in which it is involved by
treating immortalized (IHOK) and malignant human oral keratinocytes (HN12) cells with
deferoxamine (DFO).
Methods:  IL-8 production was measured by an enzyme-linked immunoabsorbent assay and
reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Electrophoretic mobility shift
assays was used to determine NF-κB binding activity. Phosphorylation and degradation of the I-κB
were analyized by Western blot.
Results: IHOK cells incubated with DFO showed increased expression of IL-8 mRNA, as well as
higher release of the IL-8 protein. The up-regulation of DFO-induced IL-8 expression was higher
in IHOK cells than in HN12 cells and was concentration-dependent. DFO acted additively with IL-
1β to strongly up-regulate IL-8 in IHOK cells but not in HN12 cells. Accordingly, selective p38 and
ERK1/2 inhibitors for both kinases abolished DFO-induced IL-8 expression in both IHOK and
HN12 cells. Furthermore, DFO induced the degradation and phosphorylation of IκB, and activation
of NF-κB. The IL-8 inducing effects of DFO were mediated by a nitric oxide donor (S-
nitrosoglutathione), and by pyrrolidine dithiocarbamate, an inhibitor of NF-κB, as well as by
wortmannin, which inhibits the phosphatidylinositol 3-kinase-dependent activation of NAD(P)H
oxidase.
Conclusion: This results demonstrate that DFO-induced IL-8 acts via multiple signaling pathways
in immortalized and malignant oral keratinocytes, and that the control of IL-8 may be an important
target for immunotheraphy against human oral premalignant lesions.
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Background
Approximately 40,000 cases of cancer of the mouth and
pharynx are reported annually in the United States, and it
is the sixth most common cancer type worldwide. Over
90% of oral-pharyngeal cancers are squamous cell carci-
nomas (SCC). The 5-year survival rate for this type of can-
cer is approximately 50% and has not markedly improved
in the past 30 years [1,2]. Several chemotherapy regimes
have been clinically applied to treat oral-pharyngeal can-
cers, but none have shown to significantly improve prog-
noses [3,4]. Thus, a safe and effective anticancer target is
needed to treat oral cancer.
Iron is a critical nutritional element that is essential for a
variety of important biological processes including cell
growth and differentiation, electron transfer reactions,
and oxygen transport, activation, and detoxification [5].
Iron also has a major effect on neoplastic cell growth due
to its catalytic effect on the formation of hydroxyl radicals,
its suppression of the activity of host defense cells, and its
role in the promotion of cancer cell multiplication [6,7].
Indeed, iron chelation by deferoxamine (DFO), a bacte-
rial siderophore, has been shown to inhibit the growth of
and/or to induce apoptosis in malignant leukemia, neu-
roblastoma, melanoma, hepatoma, Kaposi's sarcoma,
and cervical cancer cell lines [8-14].
In vitro human cell lines as well as oral SCC tumors have
been used to demonstrate the increased level of some pro-
inflammatory, pro-angiogenic NF-κB dependent
cytokines in oral-pharyngeal cancers. These include TNF-
α, IL-1, IL-6, IL-8, GM-CSF, and VEGF, which have been
shown to be highly elevated in the local milieu of SCC
[15-18]. Evidence exists that the production of these
cytokines is unregulated in oral-pharyngeal SCC and that
they have roles in cell growth, invasion, interruption of
tumor suppression, immune status, and survival [15,16].
It is unknown, however, whether these mediators are crit-
ical for the development and/or growth of tumors, and
whether they create a permissive environment for the pro-
gression of malignancies [17-19].
Interleukin-8 (IL-8) was originally identified as a neu-
trophil chemotatic factor in the supernatants of activated
human monocytes [20,21]. IL-8 is a pluripotent pro-tum-
origenic cytokine that is known to induce angiogenesis,
tumor cell proliferation, and tumor cell migration [22-
25]. The local expression of IL-8 in the tumor environ-
ment likely plays an important role in cancer progression
and metastasis [26]. Therefore, it is essential to define the
activation pathways in which iron chelation controls IL-8
expression in oral cancer cells in order to develop appro-
priate therapeutic regimes.
We recently discovered that DFO inhibited the prolifera-
tion and induced the apoptosis of immortalized human
oral keratinocytes (IHOK) and oral cancer cells [27] We
also reported that p38 and ERK MAP kinase mediated
DFO-induced apoptosis and the suppression of differenti-
ation in IHOK and oral cancer cells [28]; however, an
immunomodulatory role of IL-8 against the iron chelator
DFO has not been reported in oral cancer and IHOK cells.
The purpose of this study was to determine whether DFO
affects IL-8 signaling and stabilization through mitogen-
activated protein (MAP) kinase, NF-κB pathways, post-
transcriptional mechanisms, and multiple intracellular
signal transduction in immortalized and malignant oral
keratinocytes.
Methods
Materials
DFO (deferoxamine), mimosine (MIM), ferric citrate
(FC), alkaline-phosphatase-conjugated monoclonal
mouse anti-rabbit IgG, and p-nitrophenyl phosphate tab-
lets were purchased from Sigma-Aldrich (St. Louis, MO).
All reagents and media for tissue culture experiments were
tested for their LPS contents with a colorimetric Limulus
amebocyte lysate assay (detection limit 10 pg/M Sigma-
Aldrich). Human IL-1β was obtained from Invitrogen
(Carlsbad, CA). TNF-α and polyclonal goat anti-human
IL-8 were obtained from R & D Systems (Minneapolis,
MN). SB203580 and PD98059 were purchased from Cal-
biochem (La Jolla, CA). Polyclonal rabbit anti-human IL-
8 was from Endogen (Woburn, MA). Abs against HRP-
conjugated anti-rabbit IgG was from Amersham Bio-
sciences (Little Chalfont, U.K.). Anti-human I-κBα or
antiphospho-I-κBα was from Santa Cruz Biotechnology
(Santa Cruz, CA). Dulbecco's modified Eagle's medium
(DMEM), fetal bovine serum (FBS), and other tissue cul-
ture reagents were purchased from Gibco BRL (Grand
Island, NY).
Cell culture
Informed consent was obtained from all subjects. The
study protocol was approved by ethical committee and
institutional review boards of Wonkwang University, den-
tal college, Iksan, Republic of Korea (WKDIRB 20048-13).
This study complies with the Helsinki Declaration in its
recent Korean version. The trial will also be carried out in
keeping with local legal and regulatory requirements.
HPV-immortalized human oral keratinocytes (IHOK)
were in vitro-established cell lines, which immortalized
by transfection of normal human oral keratinocytes with
PLXSN vector containing the E6/E7 open reading frames
of HPV type 16 as previously described [27-29]. The IHOK
cells were obtained from Dr. Myung-Hee Park (NIDCR,
NIH, MD), and cultured in the keratinocyte growth
medium (KGM, Gibco, Grand Islands, NY) supplementedBMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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with 2 mL of bovine pituitary extract (13 mg/ml), 0.5 ml
each of hydrocortisone (0.5 mg/ml), human epidermal
growth factor (0.5 µg/ml), insulin (5 mg/ml), epine-
phrine (0.5 mg/ml), transferrin (10 mg/ml), triiodothyro-
nine (6.5 µg/ml), and GA-1000 and 0.05 mM CaCl2.
HN12 (= HNSCC12) cells were cultured in Dulbecco's
modified Eagle's medium (DMEM, Biofluid, Rockville,
MD) containing 10% fetal bovine serum (FBS, Gibco,
USA) with 100 U/ml penicillin and 100 U/ml streptomy-
cin (Life Technologies, Gaithersburg, MD). HN12 from
metastatic carcinoma of the oral cavity [30] were obtained
from the laboratory of Dr. John F. Ensley (Wayne State
University). All the cell lines were grown at 37°C in a
humidified atmosphere of 5% CO2 and 95% air. Cells
were dissociated with 0.25% trypsin just before transfer
for experiments and were counted using a hemocytome-
ter.
IL-8 measurement
IHOK and HN12 cells were seeded at 2 × 104 into 12-well
plates (Nalge Nunc International, Rochester, NY) and cul-
tured in serum-containing medium for 24 h prior to treat-
ment. Cells were treated with fresh medium containing
stimuli as indicated. The supernatants were collected,
cleared by centrifugation, and kept at -20°C until evalua-
tion by ELISA. For measurement of IL-8 concentrations in
cell culture supernatants, 96-well microtiter plates (Max-
iSorp; Nunc) were coated with 0.2 µg/well goat anti-
human IL-8 Abs (R & D Systems) in 50 µ of PBS at 4°C
overnight. All further steps were conducted at room tem-
perature. After washing three times with PBS, nonspecific
binding sites were blocked by incubation with 150 µ PBS
+ 1% BSA/0.05% Tween-20/well for 2 h. After three
washes with PBS, 50 µ of samples or IL-8 standards were
added and incubated for 2 h. As a second antibody, 0.05
µg/well polyclonal rabbit anti-human IL-8 (Endogen) was
added and incubated for 2 h. As a third antibody, alkaline
phosphatase-labeled monoclonal mouse anti-rabbit IgG
(Sigma-Aldrich) was diluted in 50 µ of PBS + 0.1% BSA/
0.05% Tween-20 to 1:50,000 and incubated for 2 h.
Finally, alkaline phosphatase substrate p-nitrophenyl
phosphate (Sigma-Aldrich) was added at a concentration
of 1 mg/ml in 0.1 M glycine buffer (pH 10.4) containing
1 mM MgCl2 and 1 mM ZnCl2. After overnight incuba-
tion, plates were read at 405 nm on a microplate reader
(Molecular Devices, Sunnyvale, CA). The detection limit
of the ELISA was 30 pg/ml.
RNA isolation and RT-PCR
Cells (5 × 105) were grown in 60-mm culture dishes for 24
h prior to treatment, and incubated for 4–24 h in a fresh
medium containing stimuli as indicated. After discarding
growth medium, total RNA was isolated from cells using
easy-Blue (iNtRON Biotechnology, Daejon, Korea), fol-
lowing the manufacturer's instructions. Reverse transcrip-
tion of the RNA was performed using AccuPower RT
PreMix (Bioneer, Daejon, Korea). One microgram of RNA
and 20 pmol primers were preincubated at 70 degrees for
5 min and transferred to a mixture tube. The reaction vol-
ume was 20 µ. cDNA synthesis was performed at 42
degrees for 60 min, followed by RT inactivation at 94
degrees for 5 min. Thereafter, the RT-generated DNA (2–
5µ) was amplified using AccuPower PCR PreMix
(Bioneer). The primers used for cDNA amplification and
PCR conditions were as follows: IL-8 [31], 5-ATGACTTC-
CAAGCTGGCCGTGGCT-3 (sense) and 5-TCT-
CAGCCCTCTTCAAAAACTTCTC-3 (antisense); GAPDH,
5-CG GAGTCAACGGATTTGGTCGTAT-3 (sense) and 5-
AGCCTTCTCCA TGGTGGTGAAGAC-3 (antisense); an
initial denaturation at 94 degrees for 5 min; 25 cycles
being conducted for the time course measurements of IL-
8 and GAPDH and 30 cycles for the detection of mRNA
decay, each cycle with 30 s of denaturation at 94 degrees,
30 s of annealing at 62 degrees and 30 s of extension at 72
degrees; and a final dwell at 72 degrees for 7 min. The
expected PCR products were 289 bp (for IL-8) and 306 bp
(for GAPDH). PCR products were resolved on a 1.5% aga-
rose gel and stained with ethidium bromide.
Electrophoretic mobility shift assays
Cells (1 × 106) were grown in 100-mm culture dishes and
incubated for various times with DFO. Cells were
mechanically scraped in PBS and washed, then 1 × 107
cells were resuspended in 500 µl of lysis buffer A (15 mM
KCl, 10 mM HEPES, 2 mM MgCl2, 0.1 mM EDTA, 1 mM
PMSF, 1 mM dithiothreitol (DTT), 10 µg/ml aprotinin, 2
µg/ml leupeptin, 0.1% NP-40, pH 7.6). Cell suspensions
were then incubated for 10–15 min on ice with occasional
vortexing, and centrifuged for 30 s to pellet nuclei, which
were rinsed with wash buffer B (2 mM KCl, 25 mM
HEPES, 0.1 mM EDTA, 1 mM PMSF, 1 mM DTT, 10 µg/ml
aprotinin, 2 µg/ml leupeptin, pH 7.6) and incubated at
4°C for 20 min. Nuclear extracts were then prepared by
centrifugation at 20 000 × g for 15 min in buffer C (25
mM HEPES, 0.1 mM EDTA, 20% glycerol, pH 7.6) and
stored at -80° until used for EMSA. The probes contained
the NF-kB or the AP-1 oligonucleotide consensus
sequence and were labeled with γ-32P (Amersham Life Sci-
ence) (3000 Ci/mmol, 250 µCi) using T4 polynucleotide
kinase (Boehringer Mannheim). In competition assays,
100 × cold NF-kB competitor was added. The DNA-pro-
tein complex was separated on a non-denaturating 4%
polyacrylamide gel in TBE buffer (Tris-HCl, boric acid,
EDTA 2 mM, pH 8.0). After electrophoresis, the gel was
dried and autoradiographed by overnight exposure to X-
ray film.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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Cell extract preparation and Western blot analysis
IHOK and HN 12 cells (1 × 106) were grown in 100 mm-
dishes and incubated for 0.5–16 h in fresh medium con-
taing stimuli as indicated. For the analysis of phosphor-
ylation and degradation of the I-κB, stimulated cells were
rinsed twice with ice-cold PBS and then lysed in ice-cold
lysis buffer (50 mM Tris-HCl (pH 7.4), containing 150
mM NaCl, 1 % Nonidet P-40, 0.1 % SDS, 0.1 % deoxycho-
late, 5 mM sodium fluoride, 1 mM sodium orthovanad-
ate, 1 mM 4-nitrophenyl phosphate, 10 µg/M leupeptin,
10 µg/M pepstatin A, and 1 mM 4-(2-aminoethyl)benze-
nesulfonyl fluoride). Cell lysates were centrifuged at
15,000 rpm for 20 min at 4°C, and the supernatant was
mixed with a one-fourth volume of 4 × SDS sample buffer,
boiled for 5 min, and then separated through a 12 % SDS-
PAGE gel. After electrophoresis, proteins were transferred
to a nylon membrane by means of Trans-Blot SD semidry
transfer cell (Bio-Rad, Hercules, CA). The membrane was
blocked in 5 % skim milk (1 h), rinsed, and incubated
with primary antibody (for phosphorylated MAPKs or I-
κB) in TBST and 3 % skim milk overnight at 4°C. Excess
primary antibody was then removed by washing the
membrane four times in TBST, and the membrane was
incubated with 0.1 µg/M peroxidase-labeled secondary
antibody (against rabbit) for 1 h. Following three washes
in TBST, bands were visualized by ECL Western blotting
detection reagents and exposed to x-ray film.
Statistical analysis
Differences among groups were analyzed using one-way
analysis of variance combined with the Bonferroni test.
All values were expressed as means ± standard deviations,
and differences were considered significant at p < 0.05.
Results
Effects of Iron chelators on IL-8 expression in IHOK and 
HN12 cells
We examined whether chelation of iron from immortal-
ized human oral keratinocyte (IHOK) and oral squamous
cell carcinoma cells (HN12) was sufficient to induce a sig-
nal that would increase the production IL-8. We found
that IL-8 secretion was elevated upon exposure to DFO in
immortalized IHOK cells, but no significant change in IL-
8 concentration was seen in HN12 cells (Fig. 1A). The
effect of DFO was concentration-dependent in the range
of 0 to 2 mM; however, higher concentrations of DFO did
not increase the production of IL-8. Maximal IL-8 produc-
tion was achieved using 0.75 mM DFO in IHOK cells (Fig.
1A).
MIM is an iron chelator that is structurally distinct from
DFO. MIM also induced IL-8 secretion in IHOK cells, but
again, no significant change was observed in HN12 cells
(Fig. 1B). Conversely, the addition of FC (Fe3+, 0.5 mM)
significantly prevented DFO-induced IL-8 production
(Fig. 1B), indicating that the target of DFO is specific for
intracellular iron in IHOK cells. As shown in Fig. 1C, the
IL-8 concentrations induced by DFO were comparable to
those induced by IL-1β (10 ng/ml) and TNF-α (10 ng/ml),
and combining DFO with IL-1β had an additive effect on
IL-8 secretion in IHOK cells. Conversely, IL-8 secretion
did not differ significantly between the DFO and the DFO
plus cytokine treatments in HN12 cells (Fig. 1D).
We found that DFO induced IL-8 secretion in IHOK and
HN12 cells in a time-dependent manner (Fig. 2), and that
maximal induction occurred after 16 h of incubation (Fig.
2A and 2C). This is different from that observed in IL-1β
elicited IL-8 secretion, where a plateau of IL-8 reached
within 24 h after IL-1β treatment in IHOK cells. We also
found that the increase of IL-8 protein secretion appears
to correspond to increased IL-8 mRNA levels in IHOK
cells (Fig. 2B).
Iron chelator induces IL-8 secretion in IHOK and HN12 
cells via an NF-κB-dependent mechanism
The activation of NF-κB is usually associated with the
phosphorylation of IκB-α. NF-κB is then released and
translocated to the nucleus to activate targeted gene
expression and the phosphorylated IκB-α is degraded by a
proteasome. We examined the effect of DFO on NF-κB
activation by measuring I-κBα and pI-κBα degradation
(Fig. 3), and DNA binding of NF-κB (Fig. 4). To determine
the levels of I-κBα and pI-κBα, IHOK and HN12 cells were
incubated with 1.0 mM DFO for 0.5 to 16 h. Cell lysates
were prepared to analyze the degradation and phosphor-
ylation of I-κBα by Western blot analysis using anti-I-κBα
and pI-κBα antibodies. As shown in Fig. 3, IL-1α treat-
ment induced significant I-κBα degradation in 1 h
whereas significant DFO-induced I-κBα degradation was
only seen after 16 h in IHOK and HN12 cells.
Given that NF-κB activity is dependent on a steady con-
centration of I-κB, we investigated the effect of DFO on I-
κB phosphorylation. Phosphorylated I-κB was detected
16 h after DFO stimulation in IHOK and HN12 cells (Fig.
3A and 3B). This demonstrated that the dissociation of
NF-κB from I-κB plays a crucial role in NF-κB signal trans-
duction, and that NF-κB was translocated to the nucleus
when DFO was added to IHOK and HN12 cells.
Iron chelator induces the DNA-binding activity of NF-κB in 
IHOK and HN12 cells
It has been demonstrated that NF-κB is the central regula-
tor of IL-8 gene expression (32). We therefore examined
the effect of DFO on the activation of NF-κB using the
electrophoretic mobility shift assay (EMSA) to analyze the
NF-κB binding activity of extracted proteins. The nuclear
extracts were isolated from DFO-treated IHOK and HN12
cells, and NF-κB oligomers were used as probes. WeBMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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observed that DFO-treated IHOK and HN12 cells showed
increased DNA binding of NF-κB (Fig. 4A), and that max-
imum binding activity was detected after 16 h of incuba-
tion (Fig. 4B). These results indicate that an NF-κB
dependent pathway regulates iron chelator-mediated IL-8
production in IHOK and HN12 cells.
Both p38 and ERK1/2 activation contribute to iron 
chelator induced IL-8 production in IHOK and HN12 cells
Previous studies have shown that three MAP kinase sub-
families contribute to cell survival and the induction of
apoptosis in some cell systems [33-36]. Furthermore, the
activation of p38 and ERK MAP kinase was observed dur-
ing iron deprivation-induced apoptosis in immortalized
and malignant oral keratinocytes [28]. To examine
whether the activation of p38 and ERK1/2 by DFO treat-
ment contributes to the stimulatory effect of DFO on IL-8
production, we investigated the effects of pharmacologi-
cal agents that modulate MAP kinase activities. IHOK and
HN12 cells were treated for 48 h with DFO (1.0 mM),
PD98059 (20 µM), SB203580 (20 µM), or combinations
thereof (Fig. 5). Treatment of IHOK cells with SB203580,
the selective inhibitor for p38, blocked DFO-induced IL-8
production whereas the ERK pathway inhibitor PD98059
weakly blocked IL-8 production (Fig. 5A). SB203580 and
PD98059 treatment in HN12 cells, however, did not sig-
nificantly block DFO-induced IL-8 production (Fig. 5C).
Furthermore, IL-8 secretion appeared to correspond with
the level of IL-8 mRNA accumulation in IHOK and HN12
cells (Fig. 5B and 5D).
Effects of Iron chelator on IL-8 production in immortalized (IHOK) and malignant human oral keratinocytes (HN12) Figure 1
Effects of Iron chelator on IL-8 production in immortalized (IHOK) and malignant human oral keratinocytes (HN12). Cells 
were treated for 16 h with the indicated concentrations of DFO (0.2–2 mM) in IHOK and HN12 cells (A), or DFO (1.0 mM), 
FC (0.5 mM), MIM (1.0 mM) in IHOK and HN12 cells (B), IL-1 β (10 ng/ml), TNF-α (10 ng/ml), or combinations thereof in 
IHOK (C) and HN12 (D) cells. Levels of IL-8 secretion were determined by ELISA. Results are expressed as means ± SD of 
three independent experiments. Numbers below the gels represent the intensity of IL-8 mRNA relative to GAPDH mRNA.*: 
Statistically significant difference compared to control group, p < 0.05. #: Statistically significant difference compared to DFO 
group, p < 0.05.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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Iron chelator induces IL-8 protein secretion (A, C) and IL-8 mRNA accumulation (B, D) in IHOK and HN12 cells in a time- dependent manner Figure 2
Iron chelator induces IL-8 protein secretion (A, C) and IL-8 mRNA accumulation (B, D) in IHOK and HN12 cells in a time-
dependent manner. Cells were incubated with DFO (1.0 mM) or IL1-β (10 ng/ml) for the indicated time periods. Levels of IL-8 
protein and mRNA were determined by ELISA and semiquantitative RT-PCR, respectively. Numbers below the gels represent 
the intensity of IL-8 mRNA relative to GAPDH mRNA. These data are representative of three independent experiments.
Iron chelator induced phosphorylated IκB-α in IHOK and HN12 cells on time dependent Figure 3
Iron chelator induced phosphorylated IκB-α in IHOK and HN12 cells on time dependent. Cells were treated with DFO (1.0 
mM) or IL-1α (10 ng/ml) for the indicated time periods. Levels of IκB-α, p IκB-α were determined by Western blotting. The 
protein fraction was extracted, electrophoresed, transferred to membrane and blotted with respective antibodies. These data 
are representative of three independent experiments.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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DFO induced the DNA binding activities of NF-kB in IHOK and HN12 cells Figure 4
DFO induced the DNA binding activities of NF-kB in IHOK and HN12 cells. The nuclear extracts from the cells treated with 
DFO 1.0 mM at the indicated times were incubated with [γ-32P] ATP-labeled NF-kB probe, and analyzed by EMSA. The specif-
icity of the bands was verified by adding a 10-fold excess of a completing unlabeled NF-kB probe (cold probe) to the 4 h DFO 
treated unclear proteins. The results were confirmed by two independent experiments.
The effect of inhibitor for p38 and ERK MAPK on iron chelator induced IL-8 protein secretion and IL-8 mRNA in IHOK and  HN12 cells Figure 5
The effect of inhibitor for p38 and ERK MAPK on iron chelator induced IL-8 protein secretion and IL-8 mRNA in IHOK and 
HN12 cells. IHOK (A) & HN12 cells (C) were pretreated with ERK inhibitor PD98059 and the p38 inhibitor SB203580 for 1 h 
and followed by the treatment with DFO (1.0 mM) for 16 h. Levels of IL-8 secretion and IL-8 mRNA were determined by 
ELISA and RT-PCR in IHOK (B) & HN12 cells (D). Same procedure as described in the legend to Fig. 1 was performed. Results 
are expressed as means ± SD of three independent experiments. *: Statistically significant difference compared to control 
group: p < 0.05, #: Statistically significant difference compared to DFO group, p < 0.05.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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Both p38 and ERK1/2 activation contribute to iron 
chelator induced IL-8 production via a posttranscriptional 
mechanism
The accumulation of mRNA is the result of a balance
between mRNA synthesis and degradation [37]. Given
that our results demonstrated that NF-κB is involved in
iron chelator-mediated IL-8 production in IHOK and
HN12 cells (Fig. 3), we sought to determine whether MAP
kinase activation by DFO is involved in the stabilization
of IL-8 mRNA transcripts to augment IL-8 protein secre-
tion. IHOK and HN12 cells were treated with DFO (1.0
mM) for 16 h, followed by treatment with actinomycin D
(5 µg/ml), an inhibitor of mRNA synthesis, in the pres-
ence or absence of MAP kinase inhibitors (Fig. 6). Total
RNA was isolated at various time points, and the remain-
ing IL-8 mRNA was measured by semiquantitative RT-
PCR. The inhibitory effect of SB203580 was stronger than
that of PD98059 during actinomycin D treatment for 4 h
(Fig. 6); however, the effect of MAP kinase inhibitors was
weaker in HN12 cells than in IHOK cells. The inhibition
of p38 and ERK resulted in the rapid disappearance of IL-
8 mRNA compared to actinomycin D-treated control cells,
suggesting that the posttranscriptional regulation of the
IL-8 gene transcript is dependent on the iron chelator in
IHOK and HN12 cells.
The sensitivity of DFO dependent IL-8 mRNA induction to 
various inhibitors of intracellular signal transduction in 
IHOK and HN12 cells
We examined whether DFO induces IL-8 production
through a variety of different signal transduction mecha-
nisms (Fig. 7). Recent evidence indicates that nitric oxide
(NO) influences Fe metabolism [38]. We therefore exam-
ined whether DFO induces IL-8 production via a NO-
dependent mechanism. We initially observed that cells
treated with 0.3 mM S-nitrosoglutathione (GSNO)
expressed increased levels of IL-8 mRNA. We then
observed that IHOK and HN12 cells incubated with 0.3
mM S-nitrosoglutathione (GSNO) in the presence of DFO
showed decreased IL-8 mRNA production. These results
indicated that the NO implicated in transcriptional activa-
tion of the DFO-induced IL-8 gene.
We also examined the involvement of the redox-sensitive
NF-κB transcription factor in DFO-mediated up-regula-
tion of IL-8 gene expression by co-incubation with DFO
and pyrrolidine dithiocarbamate (PDTC), an antioxidant
Iron chelator stabilized IL-8 mRNA through activation of p38 and ERK1/2 Figure 6
Iron chelator stabilized IL-8 mRNA through activation of p38 and ERK1/2. IHOK and HN12 cells were treated with DFO (1.0 
mM) for 16 h to allow accumulation of IL-8 mRNA. Cells were then treated with the mRNA synthesis inhibitor actinomycin D 
(ActD; 5 µg/ml), and either ERK pathway inhibitor (PD98059) or p38 inhibitor (SB203580). GAPDH mRNA was used as an 
endogenous control message. Same procedure as described in the legend to Fig. 1 was performed. Results are representative 
of three independent experiments.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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and potent inhibitor of NF-κB in IHOK cells. We observed
that significant inhibition of the DFO-dependent IL-8
induction by PDTC occurred in IHOK cells (Fig. 7A and
7B). Similar results were obtained with wortmannin, an
inhibitor of phosphatidylinositol 3-kinase-dependent
activation of NAD(P)H oxidase. These findings suggest
that NAD(P)H oxidase is the main source of ROS required
for DFO-dependent transcriptional activation of the IL-8
gene. Finally, DFO had a negligible effect on IL-8 gene
induction by cycloheximide (CHX) de novo protein syn-
thesis in IHOK and HN12 cells.
Discussion
Previous studies have demonstrated that IL-8 is secreted
by normal and cancerous cells, both of which exhibited
neutrophil chemotactic activity that corresponded with
immunoreactive IL-8 concentrations, thereby indicating
that carcinoma cells produce biologically active IL-8
[39,40]. Although the mechanisms governing tumor pro-
duction remain unknown, IL-8 is suspected to play a role
in the growth and production of carcinoma cells.
Iron and iron chelators have been shown to modulate
inflammatory mediators and to regulate inflammatory
process in several cell types [41,42]. Additionally, IL-8 and
iron chelators have been implicated in the regulation of
inflammation and other processes in the intestinal epithe-
lium, monocytes, and human blood leukocytes [43-45];
however, no previous study had examined the differential
modulatory effects of IL-8 in DFO signaling in immortal-
ized and malignant oral keratinocytes. Here we demon-
strated that an iron chelator used by bacteria to allow
growth in vitro activates an inflammatory response even in
the absence of conventional immunostimulatory or
inflammatory stimuli in immortalized and oral cancer
cells. We also demonstrated that the up-regulation of
DFO-induced IL-8 expression was higher in IHOK cells
than in HN12 cells (Fig. 1). Furthermore, DFO acted addi-
tively with IL-1β to up-regulate IL-8 in IHOK cells but not
in oral cancer cells (Fig. 2). Thus, differences in the IL-8
response to DFO could be found between IHOK and HN4
cells. Although both of IHOK and HN12 cell are trans-
formed human cells, the IHOKs relatively well expressed
the normal phenotypes of oral keratinocytes, representing
premalignant keratinocytes, while the HN4 cells disclosed
typical malignant features of oral cancer cells [46]. In the
previous our study, DFO-induced anticancer effect was
prominent in IHOKs but relatively sparse in oral cancer
cells [27,28]. The present data have the similar implica-
tions to IL-8 induction by iron-chelator, DFO, which is
immunologically more responsible to IHOK than HN12
cells. These results emphasize the cell-type-specific nature
of the signal transduction pathways that govern the
response to DFO, and that the extent of iron chelator-
responsiveness is also dependent on the state of cellular
differentiation.
Effect of various inhibitors on the DFO-induced IL-8 mRNA expression Figure 7
Effect of various inhibitors on the DFO-induced IL-8 mRNA expression. Cells were incubated for 16 h in the presence or 
absence of DFO 1.0 mM with and without GSNO (1.0 mM), PDTC (50 µM), hemoglobin (1 mg), wortmannin (0.5 µM), and 
cycloheximede (10 µg/ml). Same procedure as described in the legend to Fig. 1 was performed. The results are representative 
of three independent experiments.BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
Page 10 of 12
(page number not for citation purposes)
In the previous study we numerous in vitro and in vivo
experiments that examined iron metabolism, focusing on
the protective roles of heme oxygenase-1
[27,28,43,47,48], and determined that iron is a key and
essential mineral in body cells. Several other studies have
examined the role of iron chelators as anti-proliferative
and anticancer agents by performing series of experiments
using a single dose or limited dose of DFO (usually 0.1–
0.2 mM) [49,50]. More specifically, in the iron-chelator-
induced mitochondrial protection to combat ROS-medi-
ated myocardial damage, a dose-dependent increase in
cell survival was observed up to a DFO concentration of
10 mM [51]. Moreover, in our previous study [27,28],
DFO had an IC50 (concentration required for 50% growth
inhibition) of 0.99 mM for IHOK cells and 1.78 mM for
HN12 cells. Since iron chelators play an anti-oxidative
role promoting cell survival with H2O2 exposure (0.1
mM), cellular necrosis and apoptosis do not increase with
a high concentration of DFO (up to 10 mM in vitro) [51].
Hippocampal neurons from E16 CD1 mice were also
exposed to 10 mM DFO without cellular damage in an in
vitro study of DFO protection against hypoxia-inducible
factor (HIF)-1 alpha [52]. Our previous studies on DFO
examining iron chelator-induced apoptosis showed a lin-
ear increase in apoptosis up to 1 mM, at which point an
abrupt increase in cell necrosis occurred [27,28]. Because
the present study examined IL-8 induction in IHOK and
HN12 cells with DFO treatment, we did not report cell
survival data related to apoptosis, but instead referred to
our previous studies [27,28]. In the present study, to
determine the maximum dose of DFO inducing IL-8 pro-
duction, we applied DFO concentrations of up to 2 mM;
we found that the maximum IL-8 production occurred
with 0.75 mM DFO in IHOK cells, and then it decreased
gradually as the concentration was increased to 2 mM.
Therefore, although DFO is relatively safe when cells are
exposed to concentrations as high as 2 mM, the optimal
dose of DFO for inducing IL-8 in cultured cells is 0.75 mM
or less. At greater concentrations, iron metabolism might
be deleteriously affected, and an apoptosis-related reduc-
tion in cell survival could occur. As the mechanism of
DFO in apoptosis or iron-metabolism cytotoxicity is a dif-
ferent issue from its role in IL-8 production, in the present
study, we focused on the issue of IL-8 induction by DFO,
which was maximal at 0.75 mM, and referred to our pre-
vious studies for information on DFO-induced apoptosis.
The binding of NF-κB to the IL-8 promoter is essential for
the constitutive activation of IL-8 gene transcription, and
p65 is one of the major components responsible for κB
binding to the IL-8 promoter [53]. I-κBα, a member of the
I-κB family, is phosphorylated in response to TNF or IL-1
stimulation, and is thereby subjected to ubiquitination
and degradation by the 26S proteosome [54]. Degrada-
tion of I-κBα releases NF-κB for translocation to the
nucleus and the subsequent activation of target genes
[55]. In this study, we investigated DFO-induced IL-8 pro-
duction in IHOK and HN12 cells by blocking the I-κB/NF-
κB signal pathway. We noted I-κBα degradation after 16 h
of DFO exposure, whereas treatment with IL-1β signifi-
cantly induced I-κBα degradation after 1 h in IHOK and
HN12 cells (Fig. 3). Moreover, phosphorylation of the I-
κBα protein was very apparent after DFO treatment for 16
h in IHOK and HN12 cells (Fig. 3). Finally, we observed
that DFO treatment led to an increase in DNA binding
activity of NF-κB in IHOK and HN12 cells (Fig. 4). These
findings indicate that DFO mediated I-κBα degradation
and NF-κB binding induced the NF-κB-activating signal
pathway to regulate the expression of the immunomodu-
latory target gene IL-8 in immortalized and malignant oral
keratinocytes.
MAPK pathways are important in cancer pathogenesis
because they control processes that are central to malig-
nant progression such as cell growth, apoptosis, and cellu-
lar migration [33-36]. In this study, we observed that the
inhibition of p38 or ERK with SB203580 or PD98059 sig-
nificantly reduced levels IL-8 mRNA in IHOK cells (Fig.
5). We also found that an iron chelator could inhibit the
stability of IL-8 mRNA, presumably through the activa-
tion of p38 and ERK1/2 pathways (Fig. 6). In addition, we
found that differential DFO-induced regulation of p38
and ERK1/2 promoted the expression of IL-8 in IHOK and
HN12 cells. We also observed that p38 and ERK1/2 are
required for DFO-induced IL-8 secretion in IHOK and
HN12 cells, thus providing evidence that these kinases act
posttranscriptionally via a pathway involving the stabili-
zation of the IL-8 transcript. Transcription factors, usually
AP-1, C/EBPβ can be affected by p38 or ERK, and further
study of post-transcriptional mechanisms for DFO-
induced IL-8 involving p38 or ERK is thus warranted.
The mechanism that translates the iron chelator into a sig-
nal for IL-8 expression in oral cancer cells is not yet
known. In this study, we showed that DFO-induced IL-8
was lowered by GSNO, suggesting that the NO was effec-
tive at entering cells, binding Fe, and causing Fe mobiliza-
tion [38]. This also indicates that NO is the initial factor
in the signaling cascade that mediates IL-8 gene transcrip-
tional activation by DFO. NF-κB is also an important tran-
scriptional factor for IL-8 production in cancer cells.
PDTC, one of the most effective inhibitors of NF-κB,
inhibits the NO-dependent induction of the IL-8 gene
[56]. This is consistent with our finding that PDTC
blocked the IL-8 induced by DFO, suggesting that activa-
tion of NF-κB regulates IL-8 expression in IHOK and oral
cancer cells. The PI-3 kinase inhibitor wortmannin has
been reported to inhibit the production of NO-induced
IL-8 mRNA in monocytes [56]. We showed that wortman-
nin inhibited the production of DFO-induced IL-8 inBMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
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IHOK and oral cancer cells, thus suggesting that an activa-
tion of PI-3 kinase is also involved in the IL-8 pathway.
Conclusion
This study demonstrated that the chelation of intracellular
iron induces NF-κB, p38, and ERK 1/2 MAPK activation,
and results in an immunomodulatory IL-8 response in
oral cancer cells. We therefore suggest that iron chelator-
induced IL-8 may be an attractive immuno-target for oral
premalignant lesion treatment.
Abbreviations
IL-8, interleukin-8; DFO, deferoxamine; IHOK, immortal-
ized human oral kertinocytes; ERKs, extracellular-regu-
lated kinases; SCC, squamous cell carcinoma; MIM,
mimosine; FC, ferric citrate; GSNO, S-nitrosoglutathione;
PDTC, pyrrolidine dithiocarbamate (PDTC); CHX,
cycloheximide
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
HJL and JL co-designed the study with ECK, wrote the
manuscripts, performed cell culture works, enzyme-
linked immunoabsorbent assay and RT-PCR. SKL in WK
Univ. performed EMSA, stastistical analysis and assisted
in figure preparation. ECK coordinated the study with SKL
supervised the study and edited the manuscripts. All the
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Korea Research Foundation Grant funded 
by the Korean Government (MOEHRD)" (KRF-2005-041-E00366)
References
1. Licciardello JT, Spitz MR, Hong WK: Multiple primary cancer in
patients with cancer of the head and neck : Second cancer of
the head and neck, esophagus, and lung.  Int J Radiat Oncol Biol
Phys 1989, 17(3):467-476.
2. Silverman S Jr, Bahl S: Oral lichen planus update: clinical charac-
teristics, treatment responses, and malignant transforma-
tion.  Am J Dent 1997, 10(6):259-263.
3. McCann J: Texas center studies research alternative treat-
ments.  J Natl Inst 1997, 89(20):1485-1486.
4. Cassileth BR, Chapman CC: Alternative and complementary
cancer therapies.  Cancer 1996, 77(6):1026-1034.
5. Crichton RR, Ward RJ: Iron metabolism – new perspectives in
view.  Biochemistry 1992, 31(46):11255-11264.
6. Toyokuni S: Iron-induced carcinogenesis: the role of redox
regulation.  Free Radic Biol Med 1996, 20(4):553-566.
7. Weinberg ED: Iron, asbestos, and carcinogenicity.  Lancet 1989,
1(8651):1399-1400.
8. Haq RU, Werely JP, Chitambar CR: Induction of apoptosis by iron
deprivation in human leukemic CCRF-CEM cells.  Exp Hematol
1995, 23(5):428-432.
9. Becton DL, Bryles P: Deferoxamine inhibition of human neu-
roblastoma viability and proliferation.  Cancer Res 1988,
48(24):7189-7192.
10. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A,
Gelfand E, Seligman P: Neuroblastoma sensitivity to growth
inhibition by desferrioxamine. Evidence for a block in G1
phase of the cell cycle.  Cancer Res 1993, 53(17):3968-3975.
11. Richardson D, Ponka P, Baker E: The effect of the iron(III) chela-
tor, desferrioxamine, on iron and transferrin uptake by the
human malignant melanoma cell.  Cancer Res 1994,
54(3):685-689.
12. Hann HW, Stahlhut MW, Hann CL: Effect of iron and desferox-
amine on cell growth and in vitro ferritin synthesis in human
hepatoma cell lines.  Hepatology 1990, 11(4):566-569.
13. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P, Van
Vooren JP, Noel JC, Boelaert JR, Snoeck R, Heenen M: Iron chela-
tors inhibit the growth and induce the apoptosis of Kaposi's
sarcoma cells and of their putative endothelial precursors.  J
Invest Dermatol 2000, 115(5):893-900.
14. Simonart T, Boelaert JR, Mosselmans R, Andrei G, Noel JC, Clerq ED,
Snoeck R: Antiproliferative and apoptotic effects of iron che-
lators on human cervical carcinoma cells.  Gynecol Oncol 2002,
85(1):95-102.
15. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Pianta-
dosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic
progression model for head and neck cancer: implications
for field cancerization.  Cancer Res 1996, 56(11):2488-2492.
16. Dendorfer U, Oettgen P, Libermann TA: Multiple regulatory ele-
ments in the interleukin-6 gene mediate induction of pros-
taglandins, cyclic AMP and lipopolysaccharide.  Mol Cell Biol
1994, 14(7):4443-4454.
17. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith
CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa
S, Wuezado M, Hersher LL, Van Waes C: Expression of proin-
flammatory and proangiogenic cytokines in human head and
neck cancer patients.  Clin Cancer Res 1999, 5(6):1369-1379.
18. Chen Z, Smith CW, Kiel D, Van Waes C: Metastatic variants
derived following in vivo tumor progression of an in vitro
transformed squamous cell carcinoma line acquire a differ-
ential growth advantage requiring tumor-host interaction.
Clin Exp Metastasis 1997, 15(5):527-537.
19. Chen Z, Colon I, Oritz N, Callister M, Dong G, Pegram MY, Arosa-
rena O, Strome S, Nicholson JC, Van Waes C: Effects of inter-
leukin-1 a, interleukin-1 receptor antagonist, and
neutralizing antibody on proinflammatory cytokine expres-
sion by human squamous cell carcinoma lines.  Cancer Res
1998, 58(16):3668-3676.
20. Leonard EJ, Yoshimura T: Neutrophil attractant/activation pro-
tein-1 (NAP-1 [interleukin-8]).  Am J Respir Cell Mol Biol 1990,
2(6):479-486.
21. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ: Neutrophil
chemotactic factor produced by lipopolysaccharide (LPS)-
stimulated human blood mononuclear leukocytes: partial
characterization and separation from interleukin 1 (IL 1).  J
Immunol 1987, 139(3):788-793.
22. Arihiro K, Oda H, Kaneko M, Inai K: Cytokines facilitate chemo-
tactic motility of breast carcinoma cells.  Breast Cancer 2000,
7(3):221-230.
23. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner Vm,
Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived
mediator of angiogenesis.  Science 1992, 258(5089):1798-1801.
24. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression
of interleukin 8 correlates with the metastatic potential of
human melanoma cells in nude mice.  Cancer Res 1994,
54(12):3242-3247.
25. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini
PJ, Elner SG: Interleukin-8. A corneal factor that induces neo-
vascularisation.  Am J Pathol 1992, 141(6):1279-1284.
26. Bar-Eli M: Role of interleukin-8 in tumor growth and metasta-
sis of human melanoma.  Pathobiology 1999, 67(1):12-18.
27. Lee SK, Lee JJ, Lee HJ, Lee J, Jeon BH, Jun CD, Lee SK, Kim EC: Iron
chelator-induced growth arrest and cytochrome c-depend-
ent apoptosis in immortalized and malignant oral keratinoc-
ytes.  J Oral Pathol Med 2006, 35(4):218-226.
28. Lee SK, Lee HJ, Lee J, Jeon BH, Jun CD, Lee SK, Kim EC: p38 and
ERK MAP kinase mediates iron-chelator induced apoptosis
and -supressed differentiation in immortalized and malig-
nant human oral keratinocytes.  Life Sci 2006, 79(15):1419-1427.
29. Lee HJ, Guo HY, Lee SK, Jeon BH, Jun CD, Lee Sk, Park MH, Kim EC:
Effects of nicotine on proliferation, cell cycle and differentia-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:176 http://www.biomedcentral.com/1471-2407/7/176
Page 12 of 12
(page number not for citation purposes)
tion in immortalized and malignant oral keratinocytes.  J Oral
Pathol Med 2005, 34(7):436-443.
30. Cardinali MH, Pietraszkiewicz JF, Robbins KC: Tyrosine phosphor-
ylation as a marker for aberrantly regulated growth-promot-
ing pathways in cell lines derived from head and neck
malignancies.  Int J Cancer 1995, 61(1):98-103.
31. Haq RU, Werely JP, Chitambar CR: Induction of apoptosis by iron
deprivation in human leukemic CCRF-CEM cells.  Exp Hematol
1995, 23(5):428-432.
32. Tetsuya T, Masayuki A: Enhanced radiosensitization and chem-
osensitization in NF-κB-suppressed human oral cancer cells
via the inhibition of γ-irradiation-and 5-FU-induced produc-
tion of IL-6 and IL-8.  Int J Cancer 2004, 108(6):912-921.
33. Lingen MW, Polverini PJ, Bouck NP: Retinoic acid induces cells
cultured from oral squamous cell carcinomas to become
anti-angiogenic.  Am J Pathol 1996, 149(1):247-58.
34. Holtmann H, Enninga J, Kalble S, Thiefes A, Dorrie A, Broemer M,
Winzen R, Wilhelm A, Ninomiya-Tsuji J, Matsumoto K, Resch K,
Kracht M: The MAPK kinase kinase TAK1 plays a central role
in coupling the interleukin-1 receptor to both transcriptional
and RNA-targeted mechanisms of gene regulation.  J Biol
Chem 2001, 276(5):3508-3516.
35. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E,
Wallach D, Malinin NT, Cooper JA, Resch K, Kracht M: Induction of
interleukin-8 synthesis integrates effects on transcription
and mRNA degradation from at least three different
cytokine- or stress-activated signal transduction pathways.
Mol Cell Biol 1999, 19(10):6742-6753.
36. Vlahopoulos S, Boldogh I, Casola A, Brasier AR: Nuclear factor κB-
dependent induction of interleukin-8 gene expression by
tumor necrosis factor alpha: evidence for an antioxidant sen-
sitive activating pathway distinct from nuclear translocation.
Blood 1999, 94(6):1878-1889.
37. Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K, Watanabe A:
Effect of interleukin-8 on production of tumor associated
substances and autocrine growth of human liver and pancre-
atic cancer cells.  Cancer Immunol Immunother 1998, 47(1):47-57.
38. Watts RN, Ponka P, Richardson DR: Effects of nitrogen monox-
ide and carbon monoxide on molecular and cellular iron
metabolism: mirror-image effector molecules that target
iron.  Biochem J 2003, 369(3):429-440.
39. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ: Expres-
sion of interleukin-8 correlates with angiogenesis, tumori-
genicity, and metastasis of human prostate cancer cells
impanted orthotopically in nude mice.  Neoplasia 2001,
3(1):33-42.
40. Masuya D, Huanf C, Liu D, Kameyama K, Hayashi E, Yamauchi A,
Kobayashi S, Haba R, Yokomise H: The intratumoral expression
of vascular endothelial growth factors and interleukin-8 asso-
ciated with angiogenesis in non small cell lung carcinoma
patients.  Cancer 2001, 92(10):2628-2638.
41. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-
Felmayer G, Wachter H: Iron modulates interferon-gamma
effects in the human myleomonocytic cell line THP-1.  Exp
Hematol 1992, 20(5):605-610.
42. O'Brien-Ladner AR, Bulmer BM, Weisselius LJ: Differential regula-
tion of human alveolar macrophage-derived interleukin-1
beta and tumor necrosis factor-alpha by iron.  J Lab Clin Med
1998, 132(6):497-506.
43. Choi EY, Kim EC, Oh HM, Kim S, Lee HJ, Cho EY, Yoon KH, Kim EA,
Han WC, Choi SC, Hwang JY, Park C, Oh BS, Kim Y, Kimm KC, Park
KI, Chung HT, Jun CD: Iron chelator triggers inflammatory sig-
nals in human intestinal epithelial cells: involvement of p38
and extracellular signal-regulated kinase signaling pathways.
J Immunol 2004, 172(11):7069-7077.
44. Golding S, Young SP: Iron requirements of human lym-
phocytes: relative contributions of intra-and extra-cellular
iron.  Scan J Immunol 1995, 41(3):229-236.
45. Bierer BE, Nathan DG: The effects of desferrithiocin, an oral
iron chealtor in T-cell function.  Blood 1990, 76(10):2052-2059.
46. Park NH, Gujuluva CN, Baek JH, Cherrick HM, Shin KH, Min BM:
Combined oral carcinogenicity of HPV-16 and
benzo(a)pyrene: an in vitro multistep carcinogenesis model.
Oncogene 1995, 10(11):2145-2153.
47. Kim BS, Yoon KH, Oh HM, Choi EY, Kim SW, Han WC, Kim EA,
Choi SC, Kim TH, Yun KJ, Kim EC, Lyou JH, Nah YH, Chung HT, Cha
YN, Jun CD: Involvement of p38 MAP kinase during iron che-
lator-mediated apoptotic cell death.  Cell Immunol 2002,
13(10):96-106.
48. Lee SK, Park DY, Lee HJ, Lee J, Choi MK, Jeon BH, Jun CD, Kim EC:
Functional interaction between nitric oxide-induced iron
homeostasis and heme oxygenase-1 in immortalized and
malignant oral keratinocytes.  Cancer Lett 2007, 249(2):283-293.
49. Choi EY, Lee S, Oh HM, Kim YD, Choi EJ, Kim SH, Kim SW, Choi SC,
Jun CD: Involvement of protein kinase Cdelta in iron chela-
tor-induced IL-8 production in human intestinal epithelial
cells.  Life Sci 2007, 80(5):436-445.
50. Seo GS, Lee SH, Choi SC, Choi EY, Oh HM, Choi EJ, Park DS, Kim
SW, Kim TH, Nah YH, Kim S, Kim SH, You SH, Jun CD: Iron chela-
tor induces THP-1 cell differentiation potentially by modu-
lating intracellular glutathione levels.  Free Radic Biol Med 2006,
40(9):1502-1512.
51. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AMG,
Sterba M, Gersl V, Hrdina R, Ponka P, Lange JJ, Paulus WJ, Mustes RJP:
SIH – a novel lipophilic iron chelator – protects H9c2 cardi-
omyoblasts from oxidative stress-induced mitochondrial
injury and cell death.  J Mol Cell Cardiol 2005, 39(2):345-354.
52. Hamrick SE, McQuillen PS, Jiang X, Mu D, Madan A, Ferriero DM: A
role for hypoxia-inducible factor-1alpha in desferoxamine
neuroprotection.  Neurosci Lett 2005, 379(2):96-100.
53. Kunsch D, Rosen CA: NF-kappa B subunit-specific regulation of
the interleukin-8 promoter.  Mol Cell Biol 1993,
13(10):6137-6146.
54. Thanos D, Maniatis T: Virus induction of human IFN beta gene
expression requires the assembly of an enhanceosome.  Cell
1995, 83(7):1091-1100.
55. Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and
TRADD-FADD interactions define two distinct TNF recep-
tor 1 signal transduction pathways.  Cell 1996, 84(2):299-308.
56. Turpaev K, Litvinov D, Justesen J: Redox modulation of NO-
dependent induction of interleukin 8 gene in monocytic
U937 cells.  Cytokine 2003, 23(12):15-22.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/176/pre
pub